MILFORD, Mass., Aug. 26, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today recognized the Center for Proteomics at the Translational Genomics Research Institute (TGen) as a Waters Center of Innovation.
In particular, Waters recognized Dr. Konstantinos Petritis, Head of TGen's Center for Proteomics, and his team for their leadership in the research of proteomics and biomarker discovery and verification.
In a ceremony at TGen's headquarters in Phoenix, Ariz., TGen President and Research Director Dr. Jeffrey Trent told TGen employees and representatives from Waters Corporation that TGen is moving with a great sense of urgency toward helping cancer patients.
"Whether it's through our discovery-based research or our clinical programs, our focus is to provide patient benefit as quickly as we can. My hope and expectation is that in many unique ways the Waters Centers of Innovation Program will help us accelerate our research and further our goal of providing personalized medicine to each patient in the future," said Dr. Trent.
"It was Dr. Trent's vision for translational medicine that led us to the relationship we have with TGen today. By formalizing our relationship with them we want to help TGen achieve its objectives and make personalized medicine a reality, partly by taking technology to the next level. I look forward to doing good science together for years to come," said Mark Groudas, Waters Sr. Vice President, Americas Business Operations.
TGen is now among an elite group of fewer than 20 partners worldwide that are part of the Waters Centers of Innovation. While most of the member institutes of this circle are well
|SOURCE Waters Corporation|
Copyright©2010 PR Newswire.
All rights reserved